GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Medlive Technology Co Ltd (HKSE:02192) » Definitions » Cash Flow from Financing

Medlive Technology Co (HKSE:02192) Cash Flow from Financing : HK$-145.6 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Medlive Technology Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, Medlive Technology Co paid HK$0.0 Mil more to buy back shares than it received from issuing new shares. It received HK$0.0 Mil from issuing more debt. It paid HK$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent HK$132.9 Mil paying cash dividends to shareholders. It received HK$2.1 Mil on other financial activities. In all, Medlive Technology Co spent HK$130.8 Mil on financial activities for the six months ended in Dec. 2023.


Medlive Technology Co Cash Flow from Financing Historical Data

The historical data trend for Medlive Technology Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlive Technology Co Cash Flow from Financing Chart

Medlive Technology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial -3.82 -3.36 4,643.24 -24.99 -145.62

Medlive Technology Co Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,643.82 -9.09 -16.33 -11.73 -133.88

Medlive Technology Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Medlive Technology Co's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Medlive Technology Co's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-145.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medlive Technology Co  (HKSE:02192) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Medlive Technology Co's issuance of stock for the six months ended in Dec. 2023 was HK$0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Medlive Technology Co's repurchase of stock for the six months ended in Dec. 2023 was HK$0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Medlive Technology Co's net issuance of debt for the six months ended in Dec. 2023 was HK$0.0 Mil. Medlive Technology Co received HK$0.0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Medlive Technology Co's net issuance of preferred for the six months ended in Dec. 2023 was HK$0.0 Mil. Medlive Technology Co paid HK$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Medlive Technology Co's cash flow for dividends for the six months ended in Dec. 2023 was HK$-132.9 Mil. Medlive Technology Co spent HK$132.9 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Medlive Technology Co's other financing for the six months ended in Dec. 2023 was HK$2.1 Mil. Medlive Technology Co received HK$2.1 Mil on other financial activities.


Medlive Technology Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Medlive Technology Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Medlive Technology Co (HKSE:02192) Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Baijialou Chaoyang North Road, E1 Red Manor International Bonded Innovation Park, Chaoyang District, Beijing, CHN
Medlive is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms to specifically target physicians through different promotional channels. The company uses in-house and third-party content teams to produce advertising for its clients by profiling the user preferences of the physicians on the platform who drive procurement and prescription decisions. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and SaaS solution that help with medical conferences and clinical research. M3, Japan's leading digital healthcare marketing company owns 38.8% of Medlive through a joint venture.
Executives
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
M3, Inc. 2101 Beneficial owner
Sony Group Corporation 2201 Interest of corporation controlled by you
Tian Liping
Zhang Xiaofeng 2101 Beneficial owner
Liu Lingdi 2101 Beneficial owner
Tian Lixin 2101 Beneficial owner
Brown Brothers Harriman & Co. 2502 Approved lending agent
Fidelity Funds 2101 Beneficial owner
Tiantian Co., Limited

Medlive Technology Co (HKSE:02192) Headlines

No Headlines